These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25762363)

  • 1. Cost-effectiveness Analysis with Influence Diagrams.
    Arias M; Díez FJ
    Methods Inf Med; 2015; 54(4):353-8. PubMed ID: 25762363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis with unordered decisions.
    Díez FJ; Luque M; Arias M; Pérez-Martín J
    Artif Intell Med; 2021 Jul; 117():102064. PubMed ID: 34127243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markov Influence Diagrams.
    Díez FJ; Yebra M; Bermejo I; Palacios-Alonso MA; Calleja MA; Luque M; Pérez-Martín J
    Med Decis Making; 2017 Feb; 37(2):183-195. PubMed ID: 28076183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of influence diagrams to structure medical decisions.
    Nease RF; Owens DK
    Med Decis Making; 1997; 17(3):263-75. PubMed ID: 9219186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Representation and analysis of medical decision problems with influence diagrams.
    Owens DK; Shachter RD; Nease RF
    Med Decis Making; 1997; 17(3):241-62. PubMed ID: 9219185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The problem of embedded decision nodes in cost-effectiveness decision trees.
    Arias M; Díez FJ
    Pharmacoeconomics; 2014 Nov; 32(11):1141-5. PubMed ID: 25080020
    [No Abstract]   [Full Text] [Related]  

  • 7. Statistical cost-effectiveness analysis of two treatments based on net health benefits.
    Laska EM; Meisner M; Siegel C; Wanderling J
    Stat Med; 2001 Apr; 20(8):1279-302. PubMed ID: 11304742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of endovascular repair, open repair, and conservative management of splenic artery aneurysms.
    Hogendoorn W; Lavida A; Hunink MG; Moll FL; Geroulakos G; Muhs BE; Sumpio BE
    J Vasc Surg; 2015 Jun; 61(6):1432-40. PubMed ID: 25827968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine magnetic resonance imaging for idiopathic olfactory loss: a modeling-based economic evaluation.
    Rudmik L; Smith KA; Soler ZM; Schlosser RJ; Smith TL
    JAMA Otolaryngol Head Neck Surg; 2014 Oct; 140(10):911-7. PubMed ID: 25211179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of endoscopic sphenopalatine artery ligation vs arterial embolization for intractable epistaxis.
    Rudmik L; Leung R
    JAMA Otolaryngol Head Neck Surg; 2014 Sep; 140(9):802-8. PubMed ID: 25123233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An introduction to the methods of cost-effectiveness analysis.
    Drug Ther Bull; 2012 Jul; 50(7):81-4. PubMed ID: 22789768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses.
    Bala MV; Zarkin GA; Mauskopf JA
    Value Health; 2002; 5(4):338-46. PubMed ID: 12102696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simple Inclusion of Complex Diagnostic Algorithms in Infectious Disease Models for Economic Evaluation.
    Dodd PJ; Pennington JJ; Bronner Murrison L; Dowdy DW
    Med Decis Making; 2018 Nov; 38(8):930-941. PubMed ID: 30403578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of WHO guidelines on generalized cost-effectiveness analysis.
    Murray CJ; Evans DB; Acharya A; Baltussen RM
    Health Econ; 2000 Apr; 9(3):235-51. PubMed ID: 10790702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A note on confidence intervals in cost-effectiveness analysis.
    Tambour M; Zethraeus N; Johannesson M
    Int J Technol Assess Health Care; 1998; 14(3):467-71. PubMed ID: 9780533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
    Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
    J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using decision analysis to assess comparative clinical efficacy of surgical treatment of unstable ankle fractures.
    Michelson JD
    J Orthop Trauma; 2013 Nov; 27(11):642-8. PubMed ID: 23481924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.